Treatment for Moderate to Severe Atopic Dermatitis
For adults with moderate to severe atopic dermatitis, dupilumab is the recommended first-line systemic therapy, with strong evidence supporting its efficacy and an excellent safety profile. 1
First-Line Systemic Therapy: Dupilumab
Dupilumab (an IL-4 receptor antagonist) stands out as the preferred initial systemic agent based on the 2024 American Academy of Dermatology guidelines 1. All guideline workgroup members surveyed favored dupilumab as first-line therapy 1. The dosing is straightforward: 600 mg subcutaneously at initiation, then 300 mg every 2 weeks 1.
Key advantages include:
- Strong recommendation with moderate certainty evidence 1
- Over 5 years of clinical use with no major emergent safety concerns 1
- No laboratory monitoring required before or during treatment 1
- Improves comorbid allergic conditions (asthma, eosinophilic esophagitis) 2
- FDA-approved for moderate to severe AD 1
Common pitfall: Conjunctivitis occurs frequently with dupilumab 1. Counsel patients about this expected side effect and manage symptomatically.
Alternative Biologic Options
If dupilumab fails or is not tolerated, consider these FDA-approved biologics with strong recommendations 1:
Tralokinumab (IL-13 antagonist)
- 600 mg at initiation, then 300 mg every 2 weeks 1
- Somewhat less effective than dupilumab at 16 weeks based on network meta-analysis 1
- Similar safety profile to dupilumab with no major concerns 1
Lebrikizumab (IL-13 antagonist)
- 500 mg loading dose, then 250 mg every 2 weeks 3
- FDA-approved in 2024 for ages 12 and older 3
- EASI-75 response rate of 60.6% in trials 4
JAK Inhibitors: Second-Line Systemic Options
JAK inhibitors should be reserved for patients who have failed other systemic therapies (including biologics) or when those therapies are inadvisable 1. All three carry FDA restrictions reflecting this positioning.
Upadacitinib (Strong recommendation)
- Highest observed EASI-75 response rate among JAK inhibitors (73.0% at 16 weeks) 4
- Provides rapid relief of pruritus 2
- FDA-approved only after failure of other systemic therapies 1
Abrocitinib (Strong recommendation)
- EASI-75 response of 64.6% at 12 weeks 4
- FDA-approved only after failure of other systemic therapies 1
Baricitinib (Strong recommendation, off-label)
Critical safety consideration: JAK inhibitors carry greater safety concerns than biologics, including risks that require careful patient selection and monitoring 2, 5. This is why they are positioned after biologics in the treatment algorithm.
Traditional Immunosuppressants: Conditional Recommendations
These receive only conditional recommendations due to lower quality evidence and significant toxicity concerns 1:
Cyclosporine (Conditional recommendation, off-label)
- Start at 3-5 mg/kg/day 1
- Limited to 1 year of use due to toxicity 1
- Requires monitoring for renal toxicity and hypertension 1
- Historically considered first-line before biologics existed 6
Methotrexate (Conditional recommendation, off-label)
Azathioprine (Conditional recommendation, off-label)
- Second-line option historically, but lower efficacy than cyclosporine 6
Mycophenolate (Conditional recommendation, off-label)
- Limited evidence base 1
Phototherapy: Adjunctive Option
Phototherapy receives a conditional recommendation, primarily narrowband UVB 1. The main limitations are:
- Requires 2-3 treatments per week for 10-14 weeks 1
- Accessibility challenges for most patients 1
- Long-term skin cancer risk, especially with PUVA 1
What NOT to Use
Systemic corticosteroids receive a conditional recommendation AGAINST their use 1. They are associated with disease rebound and are not recommended by current guidelines despite being the only FDA-approved systemic option historically 7.
Treatment Algorithm
- Optimize topical therapy first: Topical corticosteroids, calcineurin inhibitors, or newer agents like roflumilast cream 3, 1
- If inadequate control with optimized topicals: Consider alternative diagnoses (contact dermatitis, cutaneous lymphoma) 1
- Initiate dupilumab as first-line systemic therapy 1
- If dupilumab fails or is contraindicated: Consider tralokinumab or lebrikizumab 1
- If biologics fail or are inadvisable: Consider JAK inhibitors (upadacitinib, abrocitinib, baricitinib) 1
- If targeted therapies unavailable or contraindicated: Consider traditional immunosuppressants (cyclosporine short-term, methotrexate, azathioprine) 1
Topical anti-inflammatory medications should continue concurrently with systemic therapy for maintenance, rescue treatment, or flare management 1.